Loading...
Loading...
Arrowhead Research Corporation
ARWR presents data at the
AASLD Liver Meeting 2015 in an oral presentation and
a poster showing that ARC-520, its drug candidate against chronic
hepatitis B infection (HBV), leads to robust, sustained anti-viral
effects in chimpanzees with chronic HBV. Arrowhead also describes an
important new discovery that HBV DNA integrated into the host genome is
likely an important source of HBV surface antigen (HBsAg) production,
particularly in chimps that are negative for hepatitis B e-antigen
(HBeAg). The company plans to present additional data from this study at
the 2015 Hep Dart conference in December demonstrating that two of four
HBeAg-positive chimps exhibited signs of immune reactivation, which is
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in